Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Protein Kinase Inhibitors
  • Thyroid Neoplasms

abstract

  • These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 25505208

Additional Document Info

start page

  • 1671

end page

  • 80; quiz 1680

volume

  • 12

number

  • 12